Solid Tumor-Targeting Theranostic Polymer Nanoparticle in Nuclear Medicinal Fields

Table 1

Representative radionuclides used for imaging and radiotherapy.

Radionuclide	Emission type	Half-life	Usage^1
^11C	β^+ (99.8%), γ (0.2%)	20.39 min	I
^13N	β^+ (99.8%), γ (0.2%)	9.965 min	I
^15O	β^+ (99.9%), γ (0.1%)	2.037 min	I
^18F	β^+ (96.7%), γ (3.3%)	109.8 min	I
^32P	β^− (100%)	14.24 day	T
^64Cu	β^+ (17.4%), γ (43.6%),	12.70 h	T/I
	β^− (39.0%)
^89Sr	β^− (100%)	50.53 day	T
^90Y	β^− (100%)	64.00 h	T
^99mTc	γ (>99.9%)	6.015 h	T/I
^111In	γ (100%)	2.805 day	T/I
^123I	γ (100%)	13.22 h	I
^125I	γ (100%)	59.40 day	T/I
^131I	β^−	8.021 day	T/I
^186Re	β^−, γ	3.718 day	T/I
^188Re	β^−, γ	17.00 h	T
^211At	α	7.214 h	T
^213Bi	α	2.14 min	T
^225Ac	α	10.0 day	T

Radionuclide usage for imaging and therapy are abbreviated as “I” and “T,” respectively.